DEA final orders reinforce prescribing, pharmacy and affiliate controls

What happened

Three decisions published October 7 take effect November 6. MedPharm Research’s manufacturing application was denied after findings concerning commonly controlled affiliates’ unregistered manufacturing and recreational-market diversion; the order preserves a possible separate state-medical-license application route where applicable. Wellwise’s revocation follows unresolved dispensing red flags on at least 1,360 prescriptions. Arenbii’s revocation also concerns unresolved red flags, but DEA did not sustain a separate partial-fill allegation for insufficient facts. Both pharmacy registrations had already been immediately suspended in September 2025. These are administrative orders, and MedPharm’s application denial must not be described as revocation of an existing registration.

Three decisions published October 9 take effect November 9. Maui Clinic Pharmacy dispensed about three hundred controlled-substance prescriptions from an unregistered relocated site; an accountability audit found 4,779 unexplained dosage units across overages and shortages. Alexandra Lovec’s order rests on at least 109 prescriptions without legitimate medical purpose, inadequate examinations and records, and dangerous combinations. Vladimir Romaniv’s order addresses overlapping prescriptions, orders during a patient’s incarceration without examination, false clinic records and missing supervisor details; DEA did not sustain the stated thirty-day-limit theory for the schedule V codeine preparation. His New York registrations had been suspended in November 2025 and New Jersey controlled-substance authority expired in November 2023. Organizations should use each actual order and current status, not the later effective dates, to assess authority; a general prescribing lesson would miss the distinct manufacturing, location, inventory and rejected-allegation limits.

Why it matters

The decisions distinguish unresolved dispensing red flags, site and inventory failures, inadequate prescribing and affiliated marijuana operations. These are entity-specific administrative outcomes, not criminal convictions.

Case details

agencies

DEA

entities

MedPharm Research LLC, Wellwise Pharmacy Inc., Arenbii Pharmacy LLC, L Krenk dba Maui Clinic Pharmacy, Alexandra Renee Lovec, Vladimir Romaniv

action Type

Administrative order

event Date

2026-10-09

alleged Conduct

Administrative findings concern affiliated marijuana handling, unresolved dispensing red flags, unregistered dispensing sites and inventory discrepancies, and controlled-substance prescribing outside professional practice.

resolution

Registration denial for MedPharm; revocations for the other five registrants, with stated November 6 or November 9 effective dates.

Operational lessons

• Document red-flag resolution and inventory accountability.
• Check authorized sites and actual prescriber registration status.

Sources

• Decision and Order: Medpharm Research, LLCOfficial · DEA · 2026-10-07 · Source review 2026-10-11
• Wellwise Pharmacy Inc.; Decision and OrderOfficial · DEA · 2026-10-07 · Source review 2026-10-11
• Arenbii Pharmacy LLC; Decision and OrderOfficial · DEA · 2026-10-07 · Source review 2026-10-11
• L Krenk DBA Maui Clinic Pharmacy; Decision and OrderOfficial · DEA · 2026-10-09 · Source review 2026-10-11
• Alexandra R. Lovec, A.P.R.N.; Decision and OrderOfficial · DEA · 2026-10-09 · Source review 2026-10-11
• Vladimir Romaniv, P.A.; Decision and OrderOfficial · DEA · 2026-10-09 · Source review 2026-10-11